Melinta Therapeutics, Inc. is dedicated to saving lives threatened by the global public health crisis of bacterial infections, through the development and commercialization of novel antibiotics that provide new and better therapeutic solutions. Melintaâs lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products representing many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Together, this pipeline provides Melinta with the unique ability to provide doctors and patients with a range of solutions that can meet the tremendous need for novel antibiotics treating serious infections. Source
No articles found.
Verona Pharma plc is a clinical stage biopharmaceutical company focused on the dev...
Verona Pharma plc is a clinical stage biopharma...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
Although intended for the lungs, many drugs are not given via the airway because d...
Although intended for the lungs, many drugs are...
Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in th...
Nabriva Therapeutics is a commercial-stage biop...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
Motif Bio is a clinical stage biopharmaceutical company developing novel antibioti...
Motif Bio is a clinical stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.